Powering Precision: The essential role of ctDNA testing for MRD assessment in GI malignancies - Direct

June 23, 2023

In this webinar, we explore how ctDNA can help bring clarity to common clinical scenarios including adjuvant treatment decision making, indeterminate findings and assessing treatment response.

Powering Precision: The essential role of ctDNA testing for MRD assessment in GI malignancies - Direct

Using ctDNA to help inform the management of patients with low-risk colorectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with low-risk colorectal cancer

Using ctDNA to help inform the management of patients with locally advanced rectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with locally advanced rectal cancer

The expanding role of ctDNA in colorectal cancer to optimize patient management

The expanding role of ctDNA in colorectal cancer to optimize patient management (with subtitles)

How ctDNA can transform interventional trial design for GI cancers

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Seeing the Forest Through the Trees: Using tumor-informed MRD testing to illuminate the treatment pathway in GI cancer

Personalized ctDNA testing to help guide treatment decisions in breast cancer

Webinar: Breast Cancer 2023 Data & Post-SABCS Summary

Panel Discussion: How ctDNA Testing is Informing the Management of Patients With GI Cancer - Direct

Locate and Track: ctDNA Monitoring in NSCLC with Signatera

Keith's Story

ctDNA monitoring to optimize immunotherapy treatment decisions

Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

Signatera Ordering

Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development

3988 - Natera - Tampa - Breast Cancer V6e (1)

SABCS 2022 Product Theater Section 1 - The Cycle of ctDNA in Breast Cancer